New Vice President of Production Joins Vivante GMP Solutions' Team

HOUSTON, Texas – October 27, 2009 – Vivante GMP Solutions, Inc. ("Vivante"; www.vivante-gmp.com) today announced that Craig T. Hebel has joined the company as Vice President of Production. Mr. Hebel has 18 years of experience in biologics process development and GMP manufacturing, with product experience ranging from viral vectors to monoclonal antibodies. Mr. Hebel led the GMP activities of biotech firm Introgen Therapeutics prior to that company selling its assets to Vivante. Before joining Introgen, Craig was a long-time employee of Tanox Biosystems, which was sold to Genentech for approximately $1B.

"We are all very excited that Craig is joining the Vivante team," said David Enloe, Vivante's founder, President and CEO. "Craig brings a great deal of experience not only on the GMP production side, but also in facilities and engineering, materials management and all other facets of GMP operations. Additionally, Craig's experience with biologics outside of viral production will bode well for our company as we grow in scope of projects our clients are asking us to perform."

"I am pleased to have been able to join Vivante GMP Solutions," said Hebel. "The company is growing, it has great relationships with its clients, and it is exciting to be part of this team, most of whom I worked with prior to Vivante's formation."

ABOUT VIVANTE GMP SOLUTIONS, INC.

Vivante provides its clients with flexible, disposable technology-dependent, scalable Good Manufacturing Practices (GMP) production capabilities, including the skills needed to convert early stage, lab-grade production into robust and scalable therapeutic product classes, suitable for clinical studies and commercial use. Vivante offers its clients access to its intellectual property portfolio, which includes patents, proprietary quality and validation systems, and broad GMP knowledge systems. Vivante operates a state-of-the-art GMP clean room facility which includes production and fill/finish capabilities, as well as facilities for research and development and Quality Control. In addition to its GMP manufacturing service, Vivante offers process development and optimization, Quality Control analytical testing, and on- and off-site GMP product storage and distribution to clinical trial sites. Notably, through its predecessor company, Vivante created the adenoviral reference material (ARM) that serves as the industry gold standard against which all other U.S. adenovirus-based materials are compared.

Vivante was created in 2009 as a result of the purchase out of Chapter 11 proceedings all the process and production-related assets of Introgen Therapeutics, Inc., a company that took its lead adenovirus-based product from inception in 1993 through BLA and MAA filings in 2008. Concurrent with the asset purchase, the management and technical team joined Vivante, thus assembling the critical pieces of a new CMO focused on viral development and GMP production.

For more information about Vivante, please visit www.vivante-gmp.com.